UHN


Associated tags: Kidney, IRI, Yolo Bypass, Liver, OTCQB, University Health Network, Phase, Placebo-controlled study, Reperfusion, Oxygen, Arch, Science Advances, Injury, UHN, Ischemia, Acute kidney injury, Pain management, TMX Group, Ethics, ACTU

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Wednesday, April 3, 2024
Kidney, UHN, User experience, AKI, Patient, Kidney disease, Inflammation, ACTU, Ethics, TMX Group, Pain management, Acute kidney injury, Ischemia, Injury, IRI, Science Advances, Arch, Oxygen, Reperfusion, Placebo-controlled study, Phase, University Health Network, OTCQB, Liver, Yolo Bypass, Randomness

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .
  • There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.